Drug Survival of Dupilumab, Methotrexate, and Cyclosporine A in Children With Atopic Dermatitis
This multicenter daily practice cohort study demonstrated a superior 1-year, 2-year, and 3-year overall drug survival for dupilumab, followed by MTX, with the lowest rates observed for CsA in pediatric patients with AD. This study also identified characteristics associated with discontinuation. These results provide insight into drug survival resulting from the effectiveness, safety, and tolerability of these systemic treatments in pediatric patients with AD and contribute to the optimization of patient outcomes.
Authors
- Marijke Kamsteeg (ORCID: https://orcid.org/0000-0002-1389-2971)
- Esmé Kamphuis (ORCID: https://orcid.org/0000-0002-4265-9634)
- Marjolein S. de Bruin-Weller (ORCID: https://orcid.org/0000-0002-1249-6993)
- Marieke M.B. Seyger (ORCID: https://orcid.org/0000-0003-0516-8294)
- Anouk G. M. Caron (ORCID: https://orcid.org/0000-0002-5793-2664)
- Lisa P. van der Rijst (ORCID: https://orcid.org/0000-0002-5865-8986)
- N. Tan Nguyen
- Marlies de Graaf (ORCID: https://orcid.org/0000-0001-9004-5111)
- Nicolaas P. A. Zuithoff (ORCID: https://orcid.org/0000-0002-4441-1448)
- Marie L. A. Schuttelaar (ORCID: https://orcid.org/0000-0002-0766-4382)
- Suzanne G.M.A. Pasmans (ORCID: https://orcid.org/0000-0003-1018-4475)
- Maritza A. Middelkamp‐Hup
- Rimoon Hurmuz
Institutions
- University Medical Center Groningen (NL)
- Utrecht University (NL)
- Erasmus MC (NL)
- University Medical Center Utrecht (NL)
- Amsterdam University Medical Centers (NL)
- Wilhelmina Children's Hospital (NL)
Publication Details
- Journal
- JAMA Dermatology
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1001/jamadermatol.2024.3717
- Citations
- 6
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 3.21